Gene editing

Healios bets on natural born killers

Healios is turning to natural killer cells (NK) to develop a range of new treatments which target solid tumours. Regenerative medicine innovator Healios KK has...

CRISPR in-body gene revolution gets underway

It has been an ethical minefield, but a scientific revolution. Could CRISPR in-body now be the next step in health span and lifespan therapies? Crispr...

Healios to fast-track pluripotent stem cell therapy

Healios K.K. to bring its novel regenerative pluripotent stem cell treatments to market through accelerated Japanese approvals process. Stem cell pioneers Healios KK will use...

Primetime for more powerful CRISPR tech

Researchers have developed a novel and more powerful form of CRISPR that offers the possibility to correct most disease-causing genetic variations in DNA  –...

Latest articles

Insurer puts down £20m to research an aging rethink

A new partnership between Legal & General and Edinburgh University aims to address the societal and economic implications of an aging society. The world is...

23andMe redundancies: DNA test market decline?

Could layoffs at 23andMe be a sign that the consumer appetite for genetic testing is declining? We expect consumer markets to transition to more...

Singapore agetech – ones to watch in 2020

Singapore thrives on its prime location at the crossroads of Asia's biggest markets, low business tax and great IT infrastructure; it is well-positioned to...

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.